Ritonavir raises desipramine levels and is predicted to also raise the levels of other tricyclic antidepressants.
In vitro evidence suggests that other
protease inhibitors may interact similarly, but to a lesser extent.
A lower starting dose of desipramine has been suggested, and monitoring is advisable if tricyclic antidepressants are given to patients taking
protease inhibitors.